ANDA 212491, held by Quagen. Cyproheptadine Hydrochloride.
As of Nov 16, 2026, ANDA 212491 (Cyproheptadine Hydrochloride, Cyprolara), held by Quagen, was first approved by FDA on Feb 24, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 24, 2021 | Original application | Approved | None posted |
| Cyproheptadine Hydrochloride4MG · tablet;oral | Cyproheptadine Hydrochloride | Rx |
| Cyprolara2MG · tablet;oral | Cyproheptadine Hydrochloride | Rx |
| Oct 2, 2026 | Supplement 3Manufacturing | Approved | None posted |
| Feb 24, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters